Company Overview and News


Add ALCLS
to your dashboard

Headline News

Biotech Bonanza: Biotech Stocks To Keep Shining In 2018

2017-12-19 seekingalpha
On a relative basis, Biotechs represent a good opportunity as the sector remains ~20% below its all-time high. (617-6)

BRIEF-Fda lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN

2017-11-07 reuters
* FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN (6-0)

Juno Therapeutics Inc (JUNO): 3 Reasons to Be Bullish

2017-09-27 investorplace
Juno Therapeutics Inc (NASDAQ:JUNO), which is a biotech operator that is focused on cancer treatments, has seen its stock languish during September. Yet this has come after a blistering performance. From early June, JUNO stock has logged a return of over 80%. (125-1)

Biotech Bonanza: The Next Leg Up

2017-07-25 seekingalpha
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index, as represented by ETF (IBB), gaining 17% in the first-half. The index though still remains ~29% down from its all-time high achieved in mid-2015. In comparison, the S&P 500 (SPY) was up 8%, and the Nasdaq Composite (QQQ) up 14%, in the first-half.

New Strong Buy Stocks for July 20th

2017-07-20 zacks
Agenus Inc (AGEN - Free Report) : This immuno-oncology (I-O) company has witnessed the Zacks Consensus Estimate for its current year earnings surging 10.2% over the last 30 days.

Myelodysplastic Syndrome Pipeline Therapeutic Drugs and Companies Review H1 2017 Research Report Available at RnRMarketResearch

2017-06-21 prnewswire
RnRMarketResearch.com adds "Myelodysplastic Syndrome Pipeline Review H1 2017" therapeutic market research report provides an overview of the Myelodysplastic Syndrome's therapeutic pipeline.

VC-Backed IPOs In Private Biotech: Murky, With Many Shades Of Black

2017-05-02 seekingalpha
In 2016, almost 500 private biotech companies successfully fundraised, and nearly two dozen young biotech completed IPOs.

H1 Pipeline on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) for 2017 Market Therapeutics Growth and Assessment at ReportsnReports.com

2017-04-14 prnewswire
The latest disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Review, H1 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Will Cellectis (CLLS) Continue to Surge Higher?

2017-02-10 zacks
As of late, it has definitely been a great time to be an investor in Cellectis SA (CLLS - Free Report) . The stock has moved higher by 11% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

Pfizer Inc.: Invest For Attractive Valuation And The 4% Dividend Yield

2017-02-09 seekingalpha
Pfizer Inc. (NYSE:PFE) is one of the world's largest pharmaceutical firms with sales exceeding $50 billion. The company is currently attractively valued at a blended P/E ratio of 13.3, offering a current dividend yield of 4%. Pfizer is awarded an S&P credit rating of AA and possesses a modest debt to capital ratio of 28%.

BRIEF-Cellectis says first patient treated in phase 1 trial of UCART19

2016-06-20 reuters
* Cellectis SA says first patient treated in phase 1 trial of ucart19 in pediatric acute B lymphoblastic leukemia

Second baby gets Cellectis 'designer' cells to clear leukemia - Business Insider

2016-05-06 businessinsider
LONDON (Reuters) - A second baby with aggressive leukemia has been treated in London with "designer immune cells" developed by Cellectis and, six months after treatment, she remains in remission, the French biotech firm said on Friday.

Second baby gets Cellectis 'designer' cells to clear leukemia

2016-05-06 channelnewsasia
LONDON: A second baby with aggressive leukemia has been treated in London with "designer immune cells" developed by Cellectis and, six months after treatment, she remains in remission, the French biotech firm said on Friday.

Cellectis Form 6-K (Current Report of Foreign Issuer)

2016-02-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K   Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: February, 2016 Commission File Number: 001-36891 Cellectis S.A. (Exact Name of registrant as specified in its charter)   8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual

Cellectis Form EX-99.1

2016-02-17 sec.gov
Exhibit Exhibit 99.1                                      Joint Filing Agreement Pursuant to Rule 13d-1 This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities and Exchange Act of 1934, as amended (the “Act”) by and among the parties listed below, each referenced to herein as a “Joint Filer.” The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the Rules thereunder may be filed on each of their behalf on Schedule 1